| |
Delcath Systems Reports Substantial Progress
Thu Nov 19 (PR Newswire)
Delcath Systems, Inc. , a medical technology company developing the Delcath Percutaneous Hepatic Perfusion (PHP) System, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, today reported on the Company's recent progress.
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 16B | | Price
/ Earnings: | 25.8 | | Price
/ Book: | 25.8 | | Net
Profit Margin (mrq): | 9.1% | | Price
To Free Cash Flow (mrq): | 51.6 | | Return
on Equity: | 13.7% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.6% |
|